Colorectal Cancer: Epidemiology Forecast to 2028

Monday, December 23, 2019 Cancer News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Dec. 23, 2019 /PRNewswire/ --

Colorectal Cancer: Epidemiology Forecast to 2028


Read the full report:

Colorectal cancer (CRC) is a cancer that occurs in the large intestine or large bowel (Centers for Disease Control and Prevention, 2019).Most CRCs start as abnormal growths known as polyps on the inner lining of the colon or rectum. Over time, some polyps may turn into cancer (American Cancer Society, 2018).Common symptoms of CRC are: blood in stool, stomach pain, aches or cramps that do not go away, weight loss, and a persistent change in bowel habit. CRC screening tests help to find colorectal cancer at an early stage and/or remove pre-cancerous polyps in the colon or rectum (American Cancer Society, 2018). Epidemiologists utilized country-specific cancer registries, national databases, and robust peer-reviewed journal articles to build the forecast for the diagnosed incident cases and diagnosed prevalent cases of CRC in the 8MM. The following data describes epidemiology of CRC. Epidemiologists forecast an increase in the diagnosed incident cases of CRC in the 8MM, from 827,242 cases in 2018 to 1,078,959 cases in 2028 at an AGR of 3.04% during the forecast period. The diagnosed prevalent cases of CRC in the 8MM are also expected to increase, from 5,307,305 cases in 2018 to 7,303,381 cases in 2028, at an AGR of 3.76% over the forecast period. CRC is more common in men than women and the risk of developing CRC increases with age. These trends are reflected in forecast for the diagnosed incident cases, with older age groups (ages ?65 years) contributing the highest proportion of the incident cases in the 8MM. Scope - The Colorectal Cancer (CRC) Epidemiology Report and Model provide an overview of the risk factors and global trends of CRC in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China). - The report includes a 10-year epidemiological forecast for the diagnosed incident cases of CRC segmented by sex, and age (ages ?18 years) in these markets. - The diagnosed incident cases of CRC are further segmented by stage at diagnosis (stage I, II, III, and IV), by type of molecular markers (KRAS, NRAS, MET amplification, MSI-dMMR, HER2 amplification, NTRK gene fusion, and BRAF V600E), and sidedness (right-sided and left-sided). The report also includes diagnosed incident cases of CRC by population with curable synchronous liver metastases, five-year diagnosed prevalent cases of CRC, and all-time diagnosed prevalent cases of CRC. - The colorectal cancer epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists. - The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM. - The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources. Reasons to buy The Colorectal Cancer Epidemiology series will allow you to - - Develop business strategies by understanding the trends shaping and driving the global colorectal cancer market. - Quantify patient populations in the global colorectal cancer market to improve product design, pricing, and launch plans. - Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for colorectal cancer therapeutics in each of the markets covered. - Understand magnitude of colorectal cancer population by stage at diagnosis.Read the full report: About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: US: (339)-368-6001 Intl: +1 339-368-6001

Cision View original content:

SOURCE Reportlinker

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Premium Membership Benefits

News A - Z



Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store